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Abstract 
OBJECTIVE To describe associations between alcoholic fatty liver disease (ALD) or 
non-alcoholic fatty liver disease (NAFLD) hospital admission and cardiovascular 
disease (CVD), cancer, and mortality in people with T2DM. 
RESEARCH DESIGN AND METHODS We performed a retrospective cohort study 
using linked population-based routine data from the diabetes register, hospital, 
cancer and death records for people aged 40-89 years, diagnosed with T2DM in 
Scotland 2004-2013 who had one or more hospital admission records. Liver disease 
and outcomes were identified using International Classification of Diseases codes. 
We estimated hazard ratios from Cox proportional hazards models, adjusted for key 
risk factors (aHRs). 
RESULTS There were 134,368 people with T2DM (1707 with ALD and 1452 with 
NAFLD) with mean follow-up of 4.3 years for CVD and 4.7 years for mortality. 
Among people with ALD, NAFLD or without liver disease hospital records 
respectively there were: 378, 320 and 21,873 CVD events, 268, 176 and 15,101 
cancers and 724, 221 and 16,203 deaths. For ALD and NAFLD respectively, aHRs 
(95% CIs) compared to the group with no record of liver disease were: 1.59 (1.43, 
1.76) and 1.70 (1.52, 1.90), for CVD; 40.3 (28.8, 56.5) and 19.12(11.71 31.2), for 
hepatocellular cancer (HCC); 1.28 (1.12, 1.47) and 1.10 (0.94, 1.29) for non-HCC 
cancer; 4.86 (4.50, 5.24) and 1.60 (1.40, 1.83) for all-cause mortality. 
CONCLUSIONS Hospital records of ALD or NAFLD are associated, to varying 
degrees, with increased risk of CVD, cancer and mortality in people with T2DM. 
 
Abstract Word Count: 239  
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Alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD) and type 2 
diabetes (T2DM) are common diseases and ALD or NAFLD often co-exist with 
T2DM. There is evidence of a bi-directional relationship between liver disease and 
T2DM. Both ALD and NAFLD appear to be risk factors for T2DM, and T2DM is a risk 
factor for more severe liver disease in people with ALD or NAFLD (1-6). The 
increased risk of CVD, cancer and mortality among people with type 2 diabetes, 
compared to people without diabetes, is well known (7-9). There is evidence of an 
association between NAFLD and CVD among people with and without diabetes  
although it is recognised that further information is needed in terms of describing the 
natural history of NAFLD with regard to both its hepatic and extra-hepatic 
complications(10; 11), On the basis of existing evidence it appears that more 
advanced liver disease is associated with higher risk of complications (11; 12).  
Fewer data are available for the association between ALD and key health outcomes 
in people with T2DM. It is not clear how alcoholic or non-alcoholic etiology influences 
the risk of complications of liver disease(13) although there is a suggestion that fatty 
liver probably confers increased cardiovascular risk regardless of etiology and lipid 
phenotype(14).  
In a Danish cohort with cirrhosis, of whom 10% had diabetes (and 25% had any co-
morbidity), co-morbidity was associated with synergistic increases in mortality 
compared to a matched control population (15). Another Danish study compared 
incidence of several co-morbidities (including diabetes) identified from hospital 
records over a median of 2.6 years, in people with a hospital diagnosis of alcoholic 
cirrhosis, no record of viral hepatitis or of the outcomes of interest, with age and sex 
matched controls without cirrhosis (16). During follow-up, 738 people developed 
diabetes and the hazard ratio (95% CI) was 5.54 (4.94–6.21). The authors noted that 
5 
 
the extremely high mortality among people with ALD meant that few subjects lived 
long enough to develop co-morbidity and there was the potential for confounding by 
cigarette smoking. We have not identified any studies of the effect of ALD on 
mortality, CVD and cancer among people with T2D. 
There is limited evidence for the association between NAFLD and mortality or CVD 
in people who have T2DM. A US cohort study of 337 people with T2DM, of whom 
116 were diagnosed with NAFLD based on imaging or liver biopsy, suggested 
NAFLD was associated with increased all-cause mortality [age, sex and duration of 
diabetes adjusted hazard ratio 2.2; 95% confidence interval (CI) 1.1-4.2), mean 
follow-up 10.5 years] (17). An Italian study of 2103 people with T2DM of whom 157 
had NAFLD, showed that NAFLD was associated with increased risk of incident CVD 
over 6.5 years: hazard ratio (95% CI) 1.9 (1.2-2.6) adjusted for age, sex, smoking, 
diabetes duration, LDL-cholesterol, medication and metabolic syndrome (18). 
Currently, it is not possible to identify diagnoses of common liver diseases from 
routinely collected health data at a whole population level. However, ALD and 
NAFLD can be identified from hospital records in large population-based studies with 
record linkage to identify morbidity and mortality. The aim of our study was to 
describe event rates for CVD, cancer, and mortality among a type 2 diabetes cohort 
for people ALD, NAFLD and without records of liver disease. We also aimed to 
compare relative risks of CVD, cancer, all cause and cause-specific mortality for ALD 
and NAFLD compared to the group with no record of liver disease within the type 2 
diabetes cohort. 
 
Research Design and Methods 
Study population and survival time 
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We conducted a retrospective cohort study using data from a 2014 extract of the 
Scottish Care Information-Diabetes (SCI-Diabetes) national population-based 
register (19) for people diagnosed with T2DM in Scotland between 1 January 2004 
and 31 December 2013, who were aged 40-89 years during the study period and 
had a record of one or more hospital admissions. The Information Services Division 
(ISD) of NHS National Services Scotland (NHSNSS) linked the diabetes data to 
national mortality records, the cancer registry and hospital discharge records. 
Generation of the anonymised, linked data set was approved by the Scotland A 
multi-centre research ethics committee (reference 11-AL-0225), Caldicott guardians 
and the NHSNSS Privacy Application Committee (reference 33/11). 
We excluded people with International Classification of Disease (ICD) codes for viral 
hepatitis, auto-immune hepatitis, hemochromatosis and any of cirrhosis, fibrosis, 
sclerosis or portal hypertension with no mention of ALD or NAFLD (see table 1 for 
ICD codes used to identify these conditions). Entry date to the cohort was date of 
diagnosis of diabetes. Exit date for CVD and cancer analyses was based on date of 
the first CVD event or cancer registration after diagnosis of diabetes or 31 December 
2013 for people that neither died nor had a CVD or cancer event recorded by that 
date, with censoring at date of death where appropriate. Exit date for mortality 
analyses was date of death or 31 December 2013 for survivors to that date. Follow-
up was censored at date of death from another cause for cause-specific mortality. 
Survival time for each analysis was from date of diagnosis of diabetes to censoring 
or date of exit. 
 
Exposure and outcomes 
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ALD and NAFLD were identified from the presence of the International Classification 
of Disease (ICD) codes listed in the relevant columns of Table 1 in any diagnosis 
field of a hospital admission record either before or after diagnosis of diabetes or in a 
death record. Individuals with records of both ALD and NAFLD (n=116) were 
classified as having ALD, because mention of ALD suggests that alcohol intake 
would have been higher at some point in the patient’s history, than that allowed for a 
diagnosis of NAFLD. 
CVD and date of event was identified from the presence of CVD codes as listed in 
Table 1 in any position on death and hospital records. Cancer events were identified 
from cancer registry and death records. Date of death was derived from national 
mortality records. Cause-specific mortality was defined using the codes listed in 
Table 1 in the primary cause-of-death field. 
 
Statistical analysis 
People with missing data were excluded in order to perform a complete case 
analysis. We compared the characteristics of people with and without complete data. 
Cox regression models were fitted in which ALD or NAFLD were the exposures.  
Models were adjusted for age; sex; socio-economic status (SES, described further 
below); smoking status (current, former and never smoker categories); 
hypertension/anti-hypertensive treatment, defined below; high cholesterol/lipid 
lowering treatment, defined below; glycated haemoglobin (HbA1c) using measures 
closest to date of diagnosis of diabetes, and record of CVD history, prior to diagnosis 
of T2DM. 
We used the Scottish Index of Multiple Deprivation (SIMD) 
(http://www.scotland.gov.uk/Resource/Doc/933/0115249.pdf (accessed 22 
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September 2016) as the measure of SES. SIMD is a small-area-based ranked 
measure which combines 38 indicators of deprivation across seven domains. 
Rankings of the 6,505 geographical areas recorded in SIMD were included in models 
as quintiles (fifths) of the distribution where the first and fifth quintiles correspond to 
the most and least deprived groups in the population, respectively. 
The binary marker of hypertension/anti-hypertensive treatment was derived from 
measured blood pressure (>140 mmHg systolic or > 90 mmHg diastolic) or 
prescription history of anti-hypertensives (angiotensin converting enzyme inhibitors, 
angiotensin II antagonists, beta-blocking agents, calcium channel blockers, or 
diuretics) using data recorded closest to diagnosis of diabetes. A similar approach 
was used to construct the high cholesterol/lipid-lowering treatment indicator, which 
combined measured values of serum cholesterol >5mmol/l and prescription records 
for lipid-modifying medications. 
There was little evidence of interaction between liver disease status and sex; and the 
two exceptions were marginally significant at the conventional 5% level: (i) for HCC 
mortality, the interaction of ALD with sex yielded p = 0.04; (ii) for non-HCC cancer 
mortality, the interaction of NAFLD / NASH with sex returned p = 0.05. All other 
interaction terms yielded P > 0.1. We have therefore adjusted for sex instead of 
constructing sex-specific models. 
In sensitivity analyses we excluded individuals with prevalent CVD or cancer at 
diagnosis of diabetes from a further Cox model as described above and omitted the 
prevalent CVD or cancer variables to describe the association between ALD or 
NAFLD and incident CVD or incident cancer after diagnosis of diabetes. 
All Cox models were fitted using the PHREG procedure in SAS software (Version 
9.4). Difference in direct adjusted survival curves between those with and without 
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ALD or NAFLD were obtained using SAS routines published by Wang & Zhang (20) 
and are presented graphically. 
 
Results 
We identified  a cohort of 134,368 people who were aged 40-89 years and 
diagnosed with T2DM during the study period who had a record of at least one 
hospital admissionand no record of any of viral hepatitis, auto-immune hepatitis, 
haemochromatosis or liver disease of unspecified cause and who had complete data 
for SES, smoking status, hypertension/treatment status, high cholesterol/treatment 
status and HbA1c (see figure 1 in online supplemental material for a flow chart 
describing the cohort selection). Distribution of characteristics of people who were 
excluded due to missing data were similar to those of people without liver disease in 
the study cohort. Mean age at diabetes diagnosis was 62.7 years in both groups; the 
proportion of men was 54.0% in those with missing data against 54.9% in people 
with no liver disease; and the corresponding respective proportions with prevalent 
CVD were 19.2% and 19.1%. 
The study cohort therefore included 134,368 people. Mean follow-up varied between 
4.3 years for CVD outcomes and 4.7 years for mortality. There were 1,707 people 
(1.3%) with a record of ALD and 1,452 (1.1%) with a record of NAFLD of whom 8.9% 
and 19% respectively had a record of liver biopsy. For the ALD group, the mean age 
at the first ALD-related hospital admission was 57.4 years and mean age at DM 
diagnosis for this group was 59.3 years. For the NAFLD group, the mean age at the 
first hospital admission mentioning NAFLD was 58.3 years and mean age at DM 
diagnosis was 58.7 years. There were statistically significant differences in many 
characteristics by liver disease status, partly reflecting the large sample size even 
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when absolute differences were small and of questionable clinical relevance (see 
Table 2). Key differences between groups were that people with a history of hospital 
admission with ALD and NAFLD were younger than the group without liver disease 
and there was a larger proportion of men and smokers among the ALD group and a 
smaller proportion of men among the NAFLD group than among other groups. Mean 
body mass index was lowest among the ALD group and highest among the NAFLD 
group. The number of outcomes, duration of follow-up and crude event rates by liver 
disease status are shown in Table 3. The most common causes of death among the 
“other causes” groups, regardless of liver disease status, were respiratory diseases 
which accounted for about 18% of “other” deaths in the ALD group and 30% of 
“other” deaths in the NAFLD and no liver disease groups. Diseases of the digestive 
system (including liver disease) accounted for 18% of “other” deaths in the ALD 
group, 14% in the NAFLD group  and 10% in the no liver disease groups. Other 
cardiovascular and endocrine diseases contributed 12% and 10%, 18% and 14% 
and 17% and 11% to the “other causes of death” groups for people with ALD, 
NAFLD and no liver disease respectively. 
Table 4 shows adjusted hazard ratio estimates derived from Cox models for the 
associations between ALD or NAFLD and outcomes of interest. Lung cancer was the 
most common specific cancer among the ALD and no liver disease groups but 
colorectal cancer was the most common cancer among people with history of 
NAFLD. None of the associations between liver disease and individual common 
cancers was statistically significant. 
The association with incident/recurrent CVD was similar for both types of liver 
disease. HRs for all-cause mortality were elevated for both liver disease groups and 
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were higher for the ALD group than the NAFLD group. The association with non-
HCC cancer-related incidence was statistically significant for the ALD group. 
The sensitivity analyses excluding people with prevalent CVD or cancer at diagnosis 
of diabetes resulted in similar associations to those for recurrent/incident CVD and 
cancer (see Table 1 in supplemental material). 
The differences in direct adjusted survival between people with and without history of 
hospital admission with ALD or NAFLD derived from all-cause mortality are shown in 
Figures. 2 and 3  in the supplemental material respectively. Declines in survival 
relative to the no liver disease group over time were much steeper for the ALD group 
than for the NAFLD group. 
 
Discussion 
Our novel data in a national cohort show that people with T2DM who have hospital 
records of either ALD or NAFLD are at increased risk of mortality from all-causes, 
CVD and HCC, as well as being at increased risk of incident/recurrent CVD events 
compared to people without records of liver disease. These findings extend those 
from previous studies of outcomes of cirrhosis in general populations (21-23) by 
including a wider definition of liver disease and non-fatal outcomes, separating the 
NAFLD group from the broader non-alcoholic cirrhosis group, by describing CVD 
incidence in both ALD and NAFLD groups and by limiting the study population to 
people with type 2 diabetes. 
 
The largest study to date of a general population (the Third National Health and 
Nutrition Examination Survey, NHANES III), that is relevant to our NAFLD data, 
investigated the association between hepatic steatosis and NASH identified from 
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retrospective examination of ultrasound images originally performed to identify 
gallstones and liver enzyme concentrations measured in 1988-94 and mortality up 
to 2006 (24). Mortality from all causes, cardiovascular disease, cancer, or liver 
disease among people with steatosis or steatohepatitis was similar to that among 
participants without steatosis. It is likely that NHANES III participants had mild liver 
disease, as emphasised in the correspondence following publication of the paper 
(25). It is plausible that resolution of mild liver disease occurred among some 
NHANES III participants during follow up due to lifestyle change (26). Resolution of 
mild NAFLD over time would be expected to attenuate any association between 
liver disease at baseline and premature mortality. Other important differences are 
that our study was undertaken in an older population of  people with type 2 
diabetes in contrast to the population based sample and retrospective review of 
ultrasound images for NHANES III, among whom NAFLD was identified from 
hospital records. 
A recent study reported heterogeneous associations between alcohol consumption 
and cardiovascular disease and found stronger associations between heavy 
alcohol intake and fatal cardiovascular disease (than non-fatal disease) that are 
consistent with our findings for the association between ALD and CVD mortality 
and incident/recurrent CVD (27). 
Our findings showing an association between NAFLD and cardiovascular disease 
are consistent with a recent systematic review and meta-analysis of data from 16 
prospective and retrospective studies that were not limited to people with diabetes 
(11). The meta-analysis included 34,043 people among whom 36% had NAFLD 
identified by imaging or biopsy and approximately 2,600 CVD outcomes occurred 
over a median of almost seven years of follow-up. The random effect summary 
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odds ratio for the association between NAFLD and CVD was 1.64, 95% CI 1.26–
2.13 (11). Our point estimates for the association between NAFLD and both all-
cause mortality and cardiovascular disease outcomes are similar to those of the 
small cohort studies described earlier (17) (18) but our estimates are more precise 
as would be expected given the larger study population. 
A large Finnish study identified increased incidence of multiple types of cancer in 
addition to HCC among people with severe ALD and it is possible that our study 
lacked power to detect these associations (28). NAFLD has been associated with 
increased risk of colonic cancer (29), adenomatous polyps (30) and right sided 
colonic tumours (31). Further research is required to establish whether NAFLD is 
associated with other extra-hepatic cancers. 
As for all studies using routine data there is potential for misclassification in our 
study. We identified NAFLD from hospital records in 1.1% of people with T2DM and 
at least one hospital admission record, a considerably smaller proportion than 
reported in population based studies of people with T2DM that have been able to 
characterise liver disease status more accurately (32),(33). The proportion we found 
is closer to the prevalence of clinically significant liver disease identified using liver 
ultrasound and non-invasive measures of NASH, hepatic fibrosis and systemic 
inflammation of 2.2% in participants in the Edinburgh Type 2 Diabetes Study (32). 
Markers of liver injury have only recently been included in the diabetes electronic 
health record and so were not available for use as an alternative marker of liver 
disease in this study. 
In our study, we were not able to identify people with diagnoses of liver disease 
established solely in ambulatory care and such individuals are likely have less 
severe liver disease than people with a diagnosis in hospital admission records. The 
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absolute event rates that we report for the liver disease groups are therefore likely to 
be applicable to people with T2DM who have more advanced liver disease. With the 
exception of the associations between ALD and all-cause mortality and between 
both types of liver disease and HCC incidence or mortality the strength of the 
associations between liver disease and other outcomes was modest (HRs<1.70).   
However it is important to note that people with liver disease diagnosed solely in 
ambulatory care and with undiagnosed liver disease, who form a large sub-group of 
people with type 2 diabetes, are included in our comparison group. The absolute 
risks of the outcomes of interest in this sub-group of people who, in general, have 
less severe liver disease are expected to be intermediate between people without 
liver disease and people with severe liver disease who are likely to form the majority 
of our population of people with a record of hospital admission with liver disease 
(11,12). Consequently, we expect that the relative risks describing the association 
between severe liver disease and outcomes of interest would be larger than we have 
reported if we had been able to exclude people with liver disease from the 
comparison group. It will only be possible to estimate the size of this presumed bias 
when there are robust ways of identifying people with all levels of severity of liver 
disease and their risk of outcomes of interest at a population level. Our estimates of 
the strength of the association between NAFLD and mortality or CVD are consistent 
with those of other studies that included people with the whole spectrum of NAFLD 
and in which there are fewer concerns about ascertainment and misclassification 
bias (11,17,18).  This suggests that the opposing effect of the different biases in the 
way we have identified the NAFLD and comparison groups are approximately 
balanced, but this hypothesis clearly requires testing when suitable data are 
available.   It is possible that excluding people with missing data on covariates may 
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have influenced the strength of the associations that we observed but, as noted 
above, characteristics of people with missing data were similar to those of people 
without liver disease.  
 
Although we have identified differing HRs for outcomes by liver disease status for all-
cause mortality and cancer, it is interesting that the association between liver 
disease and increased risk of incident/recurrent CVD in our study was similar for 
both ALD and NAFLD. Despite the concerns about potential bias in our study noted 
above the association between NAFLD and incident/recurrent CVD that we describe 
was similar to that reported in a meta-analysis of studies that included people without 
diabetes and used other ways of identifying NAFLD (11). These findings suggest that 
liver disease per se may influence risk of CVD although it remains possible that 
common risk factors underlie risk of both liver disease and CVD. 
We could not identify the date of diagnosis of liver disease and assumed that liver 
disease was present at diagnosis of diabetes. Mean age at diagnosis of diabetes 
and at hospital admission with first mention of liver disease was similar, suggesting 
that liver disease is likely to have been present before diagnosis of T2DM in many 
people. Our study included a relatively short median follow-up time because we 
only used data from 2004, the point from which the diabetes register in Scotland 
has been almost complete. Any time-varying effect of liver disease could only be 
investigated in a large well-characterised cohort of people that includes repeated 
assessment of liver disease and diabetes status. 
The strengths of our study include the population-based nature of the national 
electronic record that captures data for >99% of people with a diagnosis of diabetes 
in Scotland and the availability of linkage to quality-assured hospital admission, 
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cancer registration and mortality data for the whole population (for more information, 
see http://www.isdscotland.org/Products-and-Services/Data-Quality/Assessments/). 
We excluded people with no record of hospital admission from the comparator group 
to reduce bias arising from inclusion of a healthier sub-group of people with T2DM  
and people who had not had the opportunity to have liver disease or outcomes of 
interest ascertained by investigations performed during a hospital admission. We 
believe that, despite the limitations discussed above, the approach we have taken is 
the most appropriate approach to identify liver disease using routine health care data 
in population-based studies at present. It will be possible to describe longer-term 
outcomes of history of hospital admission with liver disease in future data linkages. 
 
Our data from a national cohort of people with T2DM show for the first time that 
history of hospital admission with ALD or NAFLD is associated with increases in 
incident/recurrent CVD, cancer, all-cause and selected cause-specific mortality and 
independently of major risk factors. This measure of ALD or NAFLD is therefore 
associated with further increases risk of early mortality, CVD and cancer among 
people with T2DM beyond the risks associated with T2DM and key risk factors alone 
(7-9). The early stages of ALD and NAFLD are reversible following lifestyle changes 
such as reduction in alcohol consumption, weight loss and increases in physical 
activity. Our data suggest that clinicians should support their patients with T2DM and 
liver disease to make lifestyle changes where appropriate to reduce the increased 
risks of mortality and morbidity associated with more severe liver disease as well as 
improving glycemic control. Although there is some evidence of benefit of 
pioglitazone in patients with NAFLD (34), side effects of this agent have precluded its 
widespread use. Treatment with glucagon-like peptide 1 receptor agonists is 
17 
 
effective to treat hyperglycaemia for many patients with T2DM, and treatment with 
liraglutide has also shown recent promise in some patients with NASH (35). 
However, since there are no licensed treatments for chronic liver disease and 
lifestyle change is notoriously difficult to achieve, further research is needed to 
identify effective treatments for both liver disease and its extra-hepatic complications 
among people with type 2 diabetes and to establish the role of differential follow-up 
among people with diabetes and liver disease. 
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Table 1 
International Classification of Disease (ICD) codes used to define disease groups of interest. 
Disease group Individual disease name(s) Diagnosis/procedure 
codes*  
Viral hepatitis viral hepatitis (D070.3), (D070.5), 
(D070.9); [B16, B17, 
B18]  
Autoimmune 
hepatitis and 
primary biliary 
cirrhosis 
autoimmune hepatitis and primary biliary 
cirrhosis:  
(571.4), (571.6), 
[K75.4, K74.3  
Hemochromatosis hemochromatosis 275.0) [E83.1]  
Unspecified liver 
disease 
cirrhosis                                                         
hepatic fibrosis or sclerosis or fibrosis with 
sclerosis                                                        
portal hypertension 
571.5, K74.6          
571.9, K74.0, K74.1, 
K74.2                     
572.3, K76.6 
Alcoholic liver 
disease (ALD) 
alcoholic liver disease  (571.0), (571.2), 
(571.3), [K70]. 
Non-alcoholic fatty 
liver disease 
(NAFLD) 
other chronic non-alcoholic liver disease    
fatty (change of) liver, not elsewhere 
classified                                                     
non-alcoholic steatohepatitis 
571.8                              
K76.                                                                
K75.8 
Cardiovascular 
disease (CVD) 
mortality 
coronary heart disease                           
cerebrovascular disease                                              
heart failure                                                     
sudden cardiac death  
I20-I25                            
I60-I69, G45                            
I50                                        
I46.1 
Liver disease 
mortality 
all liver disease except HCC,  toxic liver 
disease and liver diseases classified 
elsewhere 
K70, K72-76 
Other mortality all other causes of death Any code not in the 
above four cells 
Prevalent and 
incident CVD 
acute coronary syndrome/ myocardial 
infarction                                                                  
stroke                                                                
heart failure                                                            
coronary revascularisation procedures and                                                                           
carotid revascularisation procedures 
410, I20-I22              
431-437, I61, I63, I64                 
428, I50                                   
K40-K46, K49, K50.1, 
K50.8, K75 and
L29.4, L29.5, L31.1, 
L34.4 
Hepatocellular 
carcinoma (HCC) 
hepatocellular carcinoma C22.0 
Other cancer 
mortality 
all cancer except HCC All C codes except 
C22.0 
 
*ICD-9 codes are numerical, ICD-10 codes are alpha-numerical, fourth revision of the Office 
for Population Censuses and Surveys procedure codes are given in italics. All deaths were 
coded using ICD-10 codes 
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Table 2 
Descriptive characteristics of people diagnosed with type 2 diabetes in Scotland aged 40-89 
years between 2004 and 2013 with record of one or more hospital admissions and complete 
data available, by liver disease status. 
 
Variable ALD              
(n = 1,707) 
NAFLD               
(n = 1,452) 
No liver 
disease            
(n = 131,209) 
Age (years) at diagnosis 
with diabetes: mean (SD) 
59.3 (9.8)        
p < 0.001* 
58.7 (11.0)   
p < 0.001* 
62.7 (12.0) 
Male: n (% of total) 1,219 (71.4)    
p < 0.001† 
685 (47.2)    
p < 0.001† 
72,017 (54.9) 
Deprivation: n (% of total) 
in SIMD quintile                         
1 (most deprived)                              
2                                                 
3                                                   
4                                              
5 (least deprived) 
                 
                  
593 (34.7)  
405 (23.7)  
276 (16.2)  
250 (14.6)  
183 (10.7)      
p < 0.001‡ 
                 
                  
348 (24.0) 
367 (25.3) 
275 (18.9) 
260 (17.9) 
202 (13.9)    
p = 0.201‡ 
                            
               
30,745 (23.4) 
30,111 (22.9) 
26,769 (20.4) 
24,270 (18.5) 
19,314 (14.7) 
HbA1c, mmol/mol: mean 
(SD)§ 
60.6 (25.6)     
p < 0.001ǁ 
63.7 (21.9)   
p = 0.008ǁ 
63.1 (22.6) 
BMI, kg / m2: mean (SD)§ 29.5 (6.5)       
p < 0.001* 
33.6 (6.6)     
p = 0.082# 
32.1 (6.4) 
Smoking: n (% of total) 
current smoker              
former smoker                
never smoked 
                  
770 (45.1)  
489 (28.6)  
448 (26.2)      
p < 0.001‡ 
                 
375 (25.8) 
500 (34.4) 
577 (39.7)     
p = 0.008‡ 
             29,409 
(22.4) 47,916 
(36.5) 53,884 
(41.1) 
Systolic BP, mm Hg: mean 
(SD)§,** 
135(19.5)       
p < 0.001* 
137 (17.7)    
p = 0.002# 
138 (17.9) 
Hypertensive/on treatment: 
n (% of total) 
1,568 (91.9)   
p < 0.001† 
1,307 (90.0)  
p = 0.027† 
115,623 (88.1) 
Total cholesterol, mmol/l: 
mean (SD)§,i 
5.0 (1.5)         
p < 0.001* 
5.2 (1.5)       
p = 0.021* 
5.1 (1.3) 
High cholesterol/on 
treatment: n (% of total) 
1,314 (77.0)   
p < 0.001† 
1,309 (90.2) 
p = 0.073† 
120,209 (91.5) 
History of CVD before 
diabetes: n (% of total) 
315 (18.4)      
p = 0.556† 
276 (19.0)    
p = 1.000† 
25,008 (19.1) 
History of cancer before 
diabetes: n (% of total) 
188 (11.0)      
p < 0.001† 
259 (17.8)    
p = 0.033† 
20,687 (15.8) 
 
All hypothesis test results (p values) represent comparison of specific liver disease group 
(e.g. ALD) with the ‘no liver disease’ group (rightmost column of table). 
*Two-sample t-test (equality of variances rejected, so degrees of freedom derived via 
Satterthwaite’s approximation [Satterthwaite, 1946]). 
†Fisher’s exact test. 
‡Chi-square test. 
§Value is that measured at closest point in time to date of diagnosis with diabetes. 
ǁMann-Whitney test. 
¶Numbers of missing values are: 449 (ALD), 359 (NAFLD / NASH), 32,828 (no liver disease). 
#Two-sample t-test (equality of variances assumption upheld). 
**Numbers of missing values are: 10 (ALD), 11 (NAFLD / NASH), 528 (no liver disease)  
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Table 3 
Outcomes, duration of follow-up and crude event rates for people diagnosed with type 2 
diabetes in Scotland aged 40-89 years between 2004 and 2013 with one or more hospital 
admission records and complete data available, by liver disease status. 
 
 ALD                                
(n = 1,707) 
NAFLD                            
(n = 1,452) 
No liver disease                 
(n = 131,209) 
outcome event
s 
person
-years 
(p-y) 
event 
rates 
per 
1,00
0 p-y 
event
s 
person
-years 
(p-y) 
event 
rates 
per 
1,00
0 p-y 
events person-
years  
(p-y) 
event 
rates 
per 
1,00
0 p-y 
incident/ 
recurren
t CVD 
378 6,746 56.0 320 6,219 51.5 21,87
3 
567,204 38.6 
incident/ 
recurren
t HCC 
64 7,262 8.8 19 7,054 2.7 114 618,794 0.2 
incident/ 
recurren
t cancer 
excl. 
HCC 
204 7,003 29.1 157 6,720 23.4 14,98
7 
586,336 25.6 
all-
cause 
mortality 
724 
7,346 
98.6 221 
7,092 
31.2 16,20
3 
618,871
2 
26.2 
CVD 
mortality 
75 10.2 41 5.8 4428 7.2 
HCC 
mortality 
36 4.9 8 1.1 153 0.2 
cancer 
mortality 
excl. 
HCC 
72 9.8 38 5.4 5,474 8.8 
other 
causes 
of death 
179 24.4 80 11.3 6,133 9.9 
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Table 4 
Associations between history of hospital admission with alcoholic liver disease (ALD) or non-
alcoholic fatty liver disease (NAFLD) and incident/recurrent CVD, cancer and mortality 
among people with type 2 diabetes with one or more hospital admission records and no 
record of other chronic liver diseases aged 40-89 years in Scotland from 2004-2013. 
 
 Hazard ratios (95% CI) 
Outcome ALD                           
(n = 1,707) 
NAFLD          
(n=1,452) 
Incident or recurrent CVD event* 1.59 (1.43, 1.76) 1.70 (1.52, 1.90) 
Incident or recurrent HCC† 41.7 (30.0, 57.8) 19.3 (11.8, 31.4) 
Incident or recurrent cancer excluding 
HCC‡ 
1.28 (1.12, 1.47) 1.10 (0.94, 1.29) 
All-cause mortality§ 4.85 (4.49, 5.23) 1.60 (1.40, 1.83) 
CVD mortality* 2.05 (1.63, 2.58) 1.15 (0.85, 1.57) 
HCC mortality† 20.5 (13.9, 30.1) 6.16 (3.02, 12.6) 
Cancer mortality (excluding HCC)‡ 1.24 (0.98, 1.57) 0.76 (0.55, 1.04) 
Other causes of death 3.50 (3.00, 4.07) 1.60 (1.28, 1.99) 
 
Hazard ratios are expressed relative to group with no record of any of the specified liver 
disease types (n = 131,209). See text for definitions. 
*Model includes prevalent CVD (i.e. CVD diagnosed prior to diabetes) as additional 
predictor. 
†Model includes prevalent HCC as additional predictor. 
‡Model includes prevalent non-HCC cancer as additional predictor. 
§Model includes prevalent CVD and prevalent cancer (any site) as additional predictors. 
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people with type 2 diabetes and alcoholic or non-alcoholic fatty liver disease hospital 
admission”  Wild et al 
 
 
TABLE 1: Results (hazard ratios with 95% confidence limits) from sensitivity analysis of incident 
outcomes (for comparison to estimates for incident/recurrent outcomes reported in table 4). 
INCIDENT CVD                                                                                                                                           
(ALD: n = 1,392; NAFLD: n = 1,176; no liver disease: n = 106,201) 
ALD NAFLD / NASH 
1.75 (1.54, 1.99) 1.55 (1.33, 1.80) 
INCIDENT HCC                                                                                                                                           
(ALD: n = 1,699; NAFLD: n = 1,451; no liver disease: n = 131,204) 
ALD NAFLD / NASH 
40.99 (29.40, 57.14) 18.46 (11.19, 30.47) 
INCIDENT CANCER EXCLUDING HCC                                                                                                             
(ALD: n = 1,526; NAFLD: n = 1,193;no liver disease: n = 110,523) 
ALD NAFLD / NASH 
1.33 (1.13, 1.55) 1.11 (0.91, 1.35) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
 
FIGURE 1: Selection of cohort of people with type 2 diabetes of 40-89 years of age diagnosed in 
Scotland 2004-2013 who had a record of at least one hospital admission, no record of any of viral 
hepatitis, auto-immune hepatitis, haemochromatosis or liver disease of unspecified cause and who 
had complete data for socio-economic status, smoking status, hypertension/treatment status, high 
cholesterol/treatment status and HbA1c. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial cohort            
n = 173,716 
n = 155,283 
n = 153,524 
Final cohort             
n = 134,368 
No hospital admission 
n = 18,433 
Other liver disease    
n = 1,759 
Missing covariates     
n = 19,156 
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FIGURE 2: Difference in direct adjusted survival (outcome: all-cause mortality) between those with 
alcoholic liver disease (ALD) and those with no liver disease, with 95% confidence band.  Cohort is 
people diagnosed with type 2 diabetes in Scotland aged 40-89 years between 2004 and 2013, 
restricted to those with complete data available.  Values < 0 indicate reduced survival probability in 
group with ALD.  
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FIGURE 3: Difference in direct adjusted survival (outcome: all-cause mortality) between those with 
NAFLD and those with no liver disease, with 95% confidence band.  Cohort is people diagnosed with 
type 2 diabetes in Scotland aged 40-89 years between 2004 and 2013, restricted to those with 
complete data available.  Values < 0 indicate reduced survival probability in group with NAFLD.  
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